Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep;22(9):e202402940.
doi: 10.1002/cbdv.202402940. Epub 2025 May 6.

Promising Prodiginins Biological Activities

Affiliations
Review

Promising Prodiginins Biological Activities

María F Ladetto et al. Chem Biodivers. 2025 Sep.

Abstract

Prodiginins are a large family of at least 34 pyrrolic compounds, including the well-studied red pigment prodigiosin. Prodiginins are produced by several microorganisms displaying broad biological activities, including antimicrobial, antiviral, antiparasitic, antiproliferative, and immunosuppressive activities. The present review aims to compile and analyze the main physicochemical and biological properties and mechanisms of action of prodiginins for microbial disease treatment, particularly SARS-CoV-2 disease and opportunistic infections related to COVID-19. The interaction of prodigiosin, as a model molecule, with cellular membranes, potential drug delivery devices, and toxicological studies, and in silico studies using molecular dynamics showed that the prodigiosin motif, which interacts with lipids, opens a new door for the potential therapeutic use of prodiginins.

Keywords: antiviral; biocide activities; drug delivery models; in silico studies; nanodevices; prodiginins; prodigiosin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Structures of some prodiginins reported in the literature. (A) Prodigiosin; (B) undecylprodigision; (C) cylcoprodigiosin; (D) decylcycloprodigiosin; (E) streptorubine; (F) nonylprodigiosin.
FIGURE 2
FIGURE 2
Chemical equilibrium of prodigiosin isomers [41].
FIGURE 3
FIGURE 3
Chemical structure of macrocyclic prodiginins: roseophilin (A) and prodigiosin R2 (B).
FIGURE 4
FIGURE 4
Docking results (A) and molecular interactions (B) of PG against E1A viral protein respectively. The binding energy of the PG‐E1A protein complex was −4.1 (modified from [179]).
FIGURE 5
FIGURE 5
Superposition of the binding mode predicted by docking for PG (magenta) and violacein (green) at the 5γ binding site in protomer A. Both dyes were located preferentially in an environment defined by residues Phe338A, Tyr365A, Tyr369A, Ala372A, Ser373A, Phe374A, Asp405C, Glu406C, Arg408C, Gln409C, Thr415C, Gly416C, Lys417C (A). Docking pose prediction for PG (B) (A modified from [185]).
FIGURE 6
FIGURE 6
RMSD (Å) versus time plot for the MD simulation on the docking complex for PG at the 5γ binding site in protomer A (A). PG predicted pose by docking (violet) and after 50 ns of MD (orange) at the 5γ binding site in protomer A. Considering the pose resulting from MD (orange), the ligand shows π‐stacking interactions with Phe338A, Tyr365A, Phe392A, and Phe515A through two of its pyrrole groups (B).
FIGURE 7
FIGURE 7
The distances between ligand atoms and key binding site residues of the Spike protein are determined during MD simulation. The aromatic ring of Phe338A‐pyrrole A of PG (A). The aromatic ring of Tyr365A‐pyrrole C of PG (B). The aromatic ring of Phe392A‐pyrrole A of PG (C). The aromatic ring of Phe515A‐pyrrole A of PG (D).
FIGURE 8
FIGURE 8
π‐stacking interactions between the protein aromatic rings and the pyrrole rings of PG.

References

    1. Tsai S. F., Lu K. Y., Chuang H. M., and Liu C. A., “Surviving the Rookie Virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV2): The Immunopathology of a SARS‐CoV2 Infection,” Cell Transplantation 30 (2021): 963689721993769. - PMC - PubMed
    1. Perico L., Benigni A., Casiraghi F., Ng L. F. P., Renia L., and Remuzzi G., “Immunity, Endothelial Injury and Complement‐Induced Coagulopathy in COVID‐19,” Nature Reviews Nephrology 17 (2021): 46–64. - PMC - PubMed
    1. Parvu S., Müller K., Dahdal D., et al., "COVID‐19 and cardiovascular manifestations," European Review for Medical and Pharmacological Sciences 26 (2022): 4509–4519. - PubMed
    1. Gasmi A., Tippairote T., Mujawdiya P. K., et al., “Neurological Involvements of SARS‐CoV2 Infection,” Molecular Neurobiology 58 (2021): 944–949. - PMC - PubMed
    1. Kordyukova L. V. and Shanko A. V., “COVID‐19: Myths and Reality,” Biochemistry 86 (2021): 800–817. - PMC - PubMed

MeSH terms

LinkOut - more resources